Global Radioligand Therapy Market Analysis and Forecasts, 2020-2021 & 2022-2031 – Focus on Indication, Product, Biomarker, and Region –

DUBLIN – (BUSINESS WIRE) – The “Radioligand Therapy Market – A Global and Regional Analysis: Focus on Indication, Product, Biomarker, and Region – Analysis and Forecast, 2021-2031” Report has been added’s offering.

The global radioligand therapy market was valued at $ 9,754.9 million in 2020 and is projected to reach $ 16,658.4 million in 2031, according to a study by the premium market intelligence study. The study also highlights that the market is set to witness a CAGR of 4.67% over the forecast period of 2021-2031.

The study encompasses the market growth drivers, market restraining factors, opportunities, competition mapping, and segmental analysis.

This study looks at the growing prevalence of cancer, strategic initiatives by key market players, and the rise in microbial sequencing of the major factors anticipated to contribute to the growth of the global radioligand therapy market.

Data from different segments of the market have been analyzed minutely to gain a holistic view of the market. These segments include market segmented based on indication, product, biomarker, and region. Each of these segments is further categorized into sub-segments and micro-segments that compile an in-depth study.

Key insights are from in-depth interviews with 16 leading companies, market participants, and vendors.

In a comprehensive study of the global radioligand therapy market, the publisher extensively covers the following:

  • The micro-segments influencing the market

  • Market share analysis of key market players

  • Growth share analysis of companies

  • Impact of COVID-19 on the global radioligand therapy market

  • Growth analysis by indication, product, biomarker, and region

  • 16 companies for profiling and product profiling

  • Potential pipeline drugs for pipeline analysis

The report highlights the following:

  • The Radioligand Therapy Market in Emerging Opportunities

  • Impact of COVID-19 on the global radioligand therapy market

  • Radioligand therapy marketed products and potential pipeline products for the market scenario

  • Drivers promoting the growth of the market

Insightful Questions Covered to Enable Companies Take Strategic Decisions

  • How is radioligand therapy revolutionizing oncology?

  • What are the major market drivers, challenges and opportunities in the global radioligand therapy market?

  • What are the underlying structures resulting in emerging trends in the global radioligand therapy market?

  • How is the COVID-19 pandemic impacting the global radioligand therapy ecosystem?

  • What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?

  • What are the key regulatory implications in developing and developing regions of radioligand-targeted therapies?

  • What are the potential entry barriers to be expected by companies willing to enter a particular region?

  • How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:

    • Products (Approved Products and Potential Pipeline)

    • Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)

    • Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)

    • Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)

  • What are the growth opportunities for radioligand therapy companies in the region?

  • Who are the key players in leading global radioligand therapy market?

  • Which companies are the most disruptive in the future, and why?

Key Topics Covered:

1 Research Methodology

1.1 Radioligand Therapy: Research Methodology

1.2 Primary Data Sources

1.3 Secondary Data Sources

1.4 Market Estimation Model

1.5 Company Profiling for Criteria

2 Radioligand Therapy Market

2.1 Product Definition

2.1.1 Inclusion and Exclusion

2.2 Market Scope

2.2.1 Study of the Scope

2.2.2 Key Questions Answered in the Report

2.3 Market Overview

2.3.1 Market Definition

2.3.2 Radioligand Therapy of Emerging Applications Neuroendocrine Neoplasms Prostate Cancer Non-Cancerous Condition

2.3.3 Market Footprint and Growth Potential

2.3.4 COVID-19 Impact on Global Radioligand Therapy Market Impact on Radioligand Therapy Clinical Trial Disruptions and Resumptions

3 Industry Analysis

3.1 Overview

3.2 Radioligand Therapy Regulatory Approval Pathway in Challenges

3.3 Radioligand Therapy of Regulatory Scenario

3.4 Legal Requirements and Frameworks in the US

3.4.1 Clinical Trial Authorization

3.4.2 Marketing Authorization

3.4.3 NDA Submission for US FDA Guidelines

3.4.4 Post-Authorization Regulations

3.5 Legal Requirements and Frameworks in Europe

3.5.1 EMA Drug License Application Process

3.5.2 Centralized Procedure

3.5.3 Decentralized Procedure

3.5.4 Mutual-Recognition Procedure

3.5.5 National Procedure

3.6 Legal Requirements and Frameworks in Asia-Pacific

3.6.1 Legal Requirements and Frameworks in Japan

4 Pipeline Analysis

4.1 Radioligand Therapy Pipeline Analysis

4.2 Radioligand Therapy Clinical Trial Design

4.2.1 [Lu-177]-PNT2002 Product Profile [Lu-177]-PNT2002 Phase III Study Design [Lu-177]-PNT2002 Efficacy, Safety, and Tolerability (Phase II) 177Lu-PNT2002 Pharmacokinetics and Pharmacodynamics Profile (Phase I)

4.2.2 CAM H2

4.2.3 [177Lu]-NeoB

4.2.4 PNT-2003

4.2.5 ITM-11

4.2.6 177.Lu FAP-2286

4.2.7 FPI-1434

4.2.8 FPI-1966

4.2.9 177Lu-DOTA-rosopatamab

5 Market Dynamics

5.1 Overview

5.2 Impact Analysis

5.3 Market Drivers

5.3.1 Cancer of Rising Prevalence by Radioligand Therapy Demand Inclined

5.3.2 Key Market Players by Strategic Initiatives

5.3.3 Rise in Clinical Research Activity

5.4 Market Restraints

5.4.1 Treatment and Complex Reimbursement Processes with High Cost Associated

5.4.2 Generics from Increased Competition

5.5 Market Opportunities

5.5.1 Expanding Radiopharmaceutical Coverage

5.5.2 Drug Discovery in the Role of Radioligand

6 Competitive Landscape

6.1 Overview

6.2 Product Launch

6.3 Product Approvals

6.4 Synergistic Activities

6.5 Mergers and Acquisitions

6.6 Market Share Analysis (by Company), 2020

7 Global Radioligand Therapy Market, Indication, $ Million, 2020-2031

7.1 Overview

7.2 Prostate Cancer

7.3 Neuroendocrine Tumor (NETs)

7.4 Other

8 Global Radioligand Therapy Market, Products, $ Million, 2020-2031

8.1 Overview

8.2 Approved Products

8.2.1 Lutathera

8.2.2 Zytiga

8.2.3 Xtandi

8.2.4 Xofigo

8.3 Potential Pipeline

9 Global Radioligand Therapy Market, Biomarker, $ Million, 2020-2031

9.1 Overview

9.2 Prostate-Specific Membrane Antigen

9.3 Ki 67 Expression and Grading

9.4 Cytochrome P450 17A1 Inhibitor

10 Global Radioligand Therapy Market, Region, $ Million, 2020-2031

10.1 Overview

11 Markets – Competitive Benchmarking & Company Profiles

11.1 Overview

11.2 Company Overview

11.3 Role of the Global Radioligand Therapy Market

11.4 Product ASP (by Region)

11.5 Key Competitors of Company

11.6 Financials

11.7 About Key Insights The Company of Financial Health

  • Johnson & Johnson Services, Inc.

  • Pfizer Inc.

  • Amneal Pharmaceuticals LLC

  • Novartis International AG

  • POINT Biopharma Global Inc

  • Fusion Pharma

  • Clovis Oncology

  • Telix Pharmaceuticals

  • Lantheus Holdings, Inc. (Progenics Pharmaceuticals)

  • Bayer AG

  • Molecular Partners

  • ITM Isotope Technologies Munich SE

  • Curium Pharma

  • Precirix

  • Radio Medix

For more information visit this report

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button